title: [Treatment Outcomes of Adult-Onset Ewing Sarcoma: A Single-Center Retrospective Study of Five Cases].
abstract: We report the treatment outcomes of 5 cases of adult-onset Ewing sarcoma(ES)managed between 2011 and 2014. We examined prognostic factors including the primary lesion, tumor size, metastatic status, and serum LDH levels.
  
  
  RESULTS
  The locations of the primary lesions included the limbs in 1 case and the trunk in 4; the cases in the trunk had a worse prognosis than that in the limbs. Tumor size was greater than 8 cm in only 1 patient, who also displayed evidence of metastases at presentation and high LDH levels. All the patients received chemotherapy consisting of alternating vincristine, doxorubicin, and cyclophosphamide(VDC)and etoposide and ifosfamide(IE). Surgery was selected for the treatment of 4 patients, and radiotherapy was administered to 1 patient for local treatment of the tumor. A median follow-up duration of 31.6 months revealed the 2-year overall survival rate and progression-free survival rate to be 80.0%.
  
  
  CONCLUSIONS
  The prognosis of patients with adult-onset ES is poor; however, combined modality therapy, including VDC-IE, was demonstrated to improve the outcome of patients in the present study. Nevertheless, the patient with tumor size exceeding 8 cm, metastasis, and high LDH levels, relapsed 1 year after treatment, as reported previously. Further investigation is required to clarify the factors affecting prognosis in adults, and to develop effective therapies for patients with a poor prognosis.
authors.affiliation: Dept. of Medical Oncology and Hematology, Sapporo Medical University.
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Murase
authors.forename: Kohichi
authors.initials: K
authors.lastname: Takada
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Kamihara
authors.forename: Makoto
authors.initials: M
authors.lastname: Usami
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yoshida
authors.forename: Ayumi
authors.initials: A
authors.lastname: Tatekoshi
authors.forename: Akari
authors.initials: A
authors.lastname: Hashimoto
authors.forename: Yohei
authors.initials: Y
authors.lastname: Arihara
authors.forename: Naotaka
authors.initials: N
authors.lastname: Hayasaka
authors.forename: Shogo
authors.initials: S
authors.lastname: Miura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Iyama
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Sato
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Sato
authors.forename: Koji
authors.initials: K
authors.lastname: Miyanishi
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Kobune
authors.forename: Makoto
authors.initials: M
authors.lastname: Emori
authors.forename: Mitsunori
authors.initials: M
authors.lastname: Kaya
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Yamashita
authors.forename: Shintaro
authors.initials: S
authors.lastname: Sugita
authors.forename: Tadashi
authors.initials: T
authors.lastname: Hasegawa
authors.forename: Junji
authors.initials: J
authors.lastname: Kato
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000601:surgery; D016896:Treatment Outcome; D055815:Young Adult